Severe hypocalcaemia warning with osteoporosis drug

The adverse event typically occurs within weeks of starting denosumab therapy, regulators warn.
Rachel Fieldhouse

This article has been updated.

The US medicines regulator has slapped a boxed warning on the osteoporosis medication denosumab regarding the increased risk of severe hypocalcaemia in patients with advanced chronic kidney disease.